EUVIMEDEUVIMED entdecken
Multizentrische Studie

Peritransplant Radiation Therapy in Patients With Refractory or Relapsed Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant: Long-Term Results of a Retrospective Study of the Fondazione Italiana Linfomi

Mario Levis, Belinda A Campbell, Fabio Matrone, Lavinia Grapulin, Anna Di Russo, Michela Buglione, Ilenia Iamundo De Cumis, Gabriele Simontacchi, Patrizia Ciammella, Alessandro Magli, Giuliana Pascale, Sofia Meregalli und 6 weitere

International Journal of Radiation Oncology*Biology*Physics · 2023

DOI: 10.1016/j.ijrobp.2023.02.019 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2023. Verfasst von Mario Levis und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University of Torino, Torino, Italy. Electronic address: mario.levis@unito.it. Hauptthemen laut MEDLINE: Hodgkin Disease, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: In this multicenter collaboration, we report real-world data in the largest published series of long-term outcomes for patients with relapsed/refractory (r/r) Hodgkin lymphoma (HL) treated with peritransplant radiation therapy (pt-RT) and high-dose chemotherapy with autologous stem cell transplant (ASCT). METHODS AND MATERIALS: We conducted a retrospective analysis including data from 12 institutions. Eligibility required histologic diagnosis of HL, receipt of ASCT plus pt-RT between 2004 and 2014 for r/r HL, and age ≥18 years at the time of ASCT. All patients received salvage chemotherapy for maximum debulking before ASCT. Metabolic responses were scored according to the Lugano Classification. The primary endpoint was overall survival (OS). Univariate and multivariate Cox proportional hazards were calculated to estimate the effect of covariates on patients' outcome. RESULTS: One hundred thirty-one patients were eligible: 68 were male (52%), and median age at ASCT was 32 years (range, 18-70). At the time of diagnosis with r/r HL, 92 patients (70%) had limited (stage I-II) disease, and 10 patients (8%) had bulky disease. Pt-RT was given pre-ASCT in 32 patients (24%) and post-ASCT in 99 (76%); median prescribed dose was 30.6 Gy (range, 20-44 Gy). With median follow-up of 60 months, 3- and 5-year OS were 84% and 77%, while 3- and 5-year progression-free survival were 75% and 72%, respectively. On univariate and multivariate analysis, advanced stage at relapse (hazard ratio [HR], 2.18; P = .04), irradiation of >3 sites (HR, 3.69; P = .01), and incomplete metabolic response after salvage chemotherapy (HR, 2.24; P = .01) had a negative effect on OS. The sequencing of pt-RT (pre- vs post-ASCT) did not affect outcomes. CONCLUSIONS: Overall, the addition of pt-RT to ASCT for patients with r/r HL is associated with very good outcomes. Limited relapsed disease with ≤3 sites involved and achievement of complete metabolic response after salvage chemotherapy were predictive of more favorable prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseHematopoietic Stem Cell TransplantationHumansMaleAdolescentYoung AdultAdultMiddle AgedAgedFemaleRetrospective StudiesAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalStem Cell TransplantationTransplantation, AutologousSalvage TherapyRecurrence

Autor:innen und Institutionen

  • Department of Oncology, University of Torino, Torino, Italy. Electronic address: mario.levis@unito.it.
  • Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia; Department of Clinica…
  • Department of Radiation Oncology, Centro di Riferimento Oncologico di Aviano, Centro di Riferimento Oncologico-Istituto di Ricovero e Cura a Carattere Scientifico (CRO-IRCCS), Aviano, Italy.
  • Department of Radiotherapy, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
  • Department of Radiation Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.
  • Department of Radiation Oncology, University and Azienda Socio Sanitaria Territoriale (ASST) Spedali Civili, Brescia, Italy.

Zitieren

APA

Levis, M., Campbell, B. A., Matrone, F., Grapulin, L., Di Russo, A., Buglione, M., Iamundo De Cumis, I., Simontacchi, G., Ciammella, P., Magli, A., Pascale, G., Meregalli, S., MacManus, M., Fanetti, G., De Felice, F., Furfaro, G., Ciccone, G., & Ricardi, U. (2023). Peritransplant Radiation Therapy in Patients With Refractory or Relapsed Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant: Long-Term Results of a Retrospective Study of the Fondazione Italiana Linfomi. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2023.02.019

Vancouver

Levis M, Campbell BA, Matrone F, Grapulin L, Di Russo A, Buglione M, et al. Peritransplant Radiation Therapy in Patients With Refractory or Relapsed Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant: Long-Term Results of a Retrospective Study of the Fondazione Italiana Linfomi. International Journal of Radiation Oncology*Biology*Physics. 2023. doi:10.1016/j.ijrobp.2023.02.019

BibTeX
@article{Levis2023,
  author = {Levis, Mario and Campbell, Belinda A and Matrone, Fabio and Grapulin, Lavinia and Di Russo, Anna and Buglione, Michela and Iamundo De Cumis, Ilenia and Simontacchi, Gabriele and Ciammella, Patrizia and Magli, Alessandro and Pascale, Giuliana and Meregalli, Sofia and MacManus, Michael and Fanetti, Giuseppe and De Felice, Francesca and Furfaro, Gabriella and Ciccone, Giovannino and Ricardi, Umberto},
  title = {Peritransplant Radiation Therapy in Patients With Refractory or Relapsed Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant: Long-Term Results of a Retrospective Study of the Fondazione Italiana Linfomi},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2023},
  doi = {10.1016/j.ijrobp.2023.02.019}
}
Kostenlos starten →